1-3 of 3
Mark A. Ahlman
Close
Sort by
Journal Articles

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30 + lymphomas: results of a phase 1 trial

Clinical Trials & Observations
Jennifer N. Brudno, Danielle A. Natrakul, Jeremiah Karrs, Nisha Patel, Roberto Maass-Moreno, Mark A. Ahlman, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven L. Highfill, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer
Journal: Blood Advances
Blood Adv (2024) 8 (3): 802–814.
https://doi.org/10.1182/bloodadvances.2023011470
Published: 2024
Includes: Supplemental data
Journal Articles

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

Clinical Trials & Observations
Elizabeth M. Holland, Bonnie Yates, Alex Ling, Constance M. Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Michael LaLoggia, John C. Molina, Daniel A. Lichtenstein, Daniel W. Lee, John A. Ligon, Haneen Shalabi, Mark A. Ahlman, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2167–2182.
https://doi.org/10.1182/bloodadvances.2021006035
Published: 2022
Includes: Supplemental data
Journal Articles

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Clinical Trials & Observations
Nirali N. Shah, Haiying Qin, Bonnie Yates, Ling Su, Haneen Shalabi, Mark Raffeld, Mark A. Ahlman, Maryalice Stetler-Stevenson, Constance Yuan, Shuang Guo, Siyuan Liu, Stephen H. Hughes, Terry J. Fry, Xiaolin Wu
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2317–2322.
https://doi.org/10.1182/bloodadvances.2019000219
Published: 2019